In the past decade, the treatment and survival for patients with AM has improved dramatically, since several therapies, such as BRAF, CTLA4 and PD1 inhibitors, have been approved for the management of metastatic or unresectable melanoma, showing promising results in terms of effectiveness and safety [64,66]. The gene discussed is CTLA4; the disease is melanoma.